Health advocates warn Medi-Cal cuts to obesity drugs could worsen health disparities in California

Health advocates are sounding the alarm over California’s decision to eliminate Medi-Cal coverage for certain obesity medications, warning the move could have serious consequences for public health.

The policy impacts access to GLP-1 medications, a class of drugs used to treat obesity, which is widely recognized as a chronic disease. Experts say limiting access could lead to worsening health outcomes, especially for vulnerable communities.

Rhonda Smith, Executive Director of the California Black Health Network, says the decision could deepen existing health disparities across the state.

She points to social determinants of health—factors like access to healthy food, safe places to exercise, and affordable healthcare—as key reasons why obesity disproportionately affects some communities.

Many Californians live in what are known as “food deserts” or “medical deserts,” where access to nutritious food and healthcare services is limited. Without proper treatment options, obesity can lead to more serious conditions, including type 2 diabetes, heart disease, hypertension, and even certain cancers.

The impact could be especially significant for those who rely on Medi-Cal. According to advocates, a large portion of patients—particularly women of color—depend on the program for essential care and may not be able to afford these medications out of pocket.

Health experts warn that restricting access to treatment could ultimately increase long-term healthcare costs, as preventable conditions become more severe.

Advocates are encouraging residents to stay informed and seek out resources that can help them better manage their health.

Explore: NBCPalmSprings.com, where we are connecting the Valley.